1-(3-(6,7-dimetoksychinazolin-4-yloksy)fenylo)-3-(5-(1,1,1-trifluoro-2-metylopropan-2-ylo)izoksazol-3-ilo)mocznik jako modulator kinazy RAF w leczeniu chorób nowotworowych
ABRAHAM SUNNY,BHAGWAT SHRIPAD S.,CAMPBELL BRIAN T.,CHAO QI,FARAONI RAFFAELLA,HOLLADAY MARK W.,LAI ANDILIY G.,ROWBOTTOM MARTIN W.,SETTI EDUARDO,SPRANKLE KELLY G.,LAI ANDILIY
申请号：
PL15166141
公开号：
PL2947072T3
申请日:
2009.03.17
申请国别(地区):
PL
年份:
2017
代理人:
摘要：
Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. The compound is 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea, having the structure or a pharmaceutically acceptable salt, solvate, clathrate or hydrate thereof.
